Imugene Ltd (ASX:IMU, OTC:IUGNF) is preparing 10 clinical trial sites in Australia and the UK for a new PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical.
The Australian sharemarket was up today, gaining 125.30 points or 1.77% to 7,186.90 and setting a new 50-day high. Mining stocks were prominent, with the.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented findings from its PD1-Vaxx trial in non-small cell lung cancer patients at the International Association for.
Imugene (ASX:IMU) share price surges 7% as R&D efforts increase fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.